Bayer's Hyrnuo moves first-line for lung cancer in China
Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
Newsletters and Deep Dive digital magazine
Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy.
Theramex, a UK-based specialty pharma company focusing on women's health, is changing hands in a private equity deal said to be worth around £2.2bn.
As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in Q3, says CEO Bill Anderson.
Editor's Picks
Newsletters and Deep Dive
digital magazine